Reason for request
Reassessment
Summary of opinion
Favourable opinion for reimbursement as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.
Clinical Benefit
| Substantial |
The clinical benefit of BENLYSTA 200 mg (belimumab) solution for injection in pre-filled pen is substantial in the MA indication.
|
Clinical Added Value
| minor |
Considering:
- the inadequately met medical need;
- the efficacy data in adults, which can be extrapolated to children based on similar pharmaco-kinetic data in adults and children for the intravenous route;
- the absence of data in patients with severe neurological involvement, despite this being an important prognostic factor in the course of juvenile SLE;
- the absence of robust data on quality of life;
- the short-term safety profile (follow-up of 1 year) globally similar to that in adults, but with concerns relating to the long-term safety in children due to important identified risks, such as injection-related systemic hypersensitivity reactions that may be delayed in onset, and important potential risks such as serious infections (in particular, progressive multifocal leuko-encephalopathy), malignancies and psychiatric disorders (depression and suicidal behaviour);
- the absence of data on the growth and development of children;
the Committee considers that, as is the case in adults, the proprietary medicinal products BENLYSTA 120 mg and 400 mg (belimumab) powder for concentrate for solution for infusion provide a minor clinical added value (CAV IV) in the care pathway as add-on therapy in children aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.
|
| no clinical added value |
|
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
XHkLmAbCfAL6vnc2